Literature DB >> 30073880

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Kerstin Heurling1, Ruben Smith2,3, Olof T Strandberg3, Martin Schain4, Tomas Ohlsson5, Oskar Hansson3,6, Michael Schöll1,3.   

Abstract

The semi-quantitative estimate standardised uptake value ratios (SUVR) correlate well with specific binding of the tracer expressed as distribution volume ratios (DVR) for the tau positron emission tomography tracer [18F]AV-1451 uptake and are therefore widely used as proxy for tracer binding. With regard to tracer kinetic modelling, there exists a time point when SUVR deviates minimally from DVR, occurring when the specific binding reaches a transient equilibrium. Here, we have investigated whether the time to equilibrium affects the agreement between SUVR and DVR across different brain regions. We show that the time required to reach equilibrium differs across brain regions, resulting in region-specific biases. However, even though the 80-100 min post-injection time window did not show the smallest bias numerically, the disagreement between SUVR and DVR varied least between regions during this time. In conclusion, our findings suggest a regional component to the bias of SUVR related to the time to transient equilibrium of the specific binding. [18F]AV-1451 uptake should consequently be interpreted with some caution when compared across brain regions using this method of quantification. The commonly used time window 80-100 min post-injection shows the most consistent bias across regions and is recommended for semi-quantification of [18F]AV-1451.

Entities:  

Keywords:  Alzheimer’s; biomarkers; neurodegeneration; pharmacokinetics; positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 30073880      PMCID: PMC6827127          DOI: 10.1177/0271678X18791430

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  45 in total

1.  [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.

Authors:  Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

2.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

3.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.

Authors:  Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun
Journal:  J Nucl Med       Date:  2016-05-05       Impact factor: 10.057

4.  Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Authors:  Olivier Barret; David Alagille; Sandra Sanabria; Robert A Comley; Robby M Weimer; Edilio Borroni; Mark Mintun; Nicholas Seneca; Caroline Papin; Thomas Morley; Ken Marek; John P Seibyl; Gilles D Tamagnan; Danna Jennings
Journal:  J Nucl Med       Date:  2016-12-01       Impact factor: 10.057

Review 5.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

6.  Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia.

Authors:  Gregory S Day; Brian A Gordon; Kelley Jackson; Jon J Christensen; Maria Rosana Ponisio; Yi Su; Beau M Ances; Tammie L S Benzinger; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

7.  Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.

Authors:  Stefanie Schreiber; Susan M Landau; Allison Fero; Frank Schreiber; William J Jagust
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

8.  Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

Authors:  Rebecca L McNamee; Seong-Hwan Yee; Julie C Price; William E Klunk; Bedda Rosario; Lisa Weissfeld; Scott Ziolko; Michael Berginc; Brian Lopresti; Steven Dekosky; Chester A Mathis
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

Review 9.  Amyloid imaging: Past, present and future perspectives.

Authors:  Victor L Villemagne
Journal:  Ageing Res Rev       Date:  2016-01-28       Impact factor: 10.895

10.  Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; David S Knopman; Val Lowe; Prashanthi Vemuri; Michelle M Mielke; Rosebud O Roberts; Mary M Machulda; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2017-04-26       Impact factor: 44.182

View more
  3 in total

Review 1.  Biomarkers for tau pathology.

Authors:  Michael Schöll; Anne Maass; Niklas Mattsson; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; William Jagust
Journal:  Mol Cell Neurosci       Date:  2018-12-07       Impact factor: 4.314

2.  Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders.

Authors:  Cheng-Hsuan Li; Ta-Fu Chen; Ming-Jang Chiu; Ruoh-Fang Yen; Ming-Chieh Shih; Chin-Hsien Lin
Journal:  Front Aging Neurosci       Date:  2021-03-29       Impact factor: 5.750

Review 3.  Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.

Authors:  E E Wolters; A Dodich; M Boccardi; J Corre; A Drzezga; O Hansson; A Nordberg; G B Frisoni; V Garibotto; R Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.